health
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from a discrete choice experiment highlighting preferred healthcare provider (HCP) treatment attributes when selecting a VMAT2 inhibitor for the treatment of TD in older patients (aged ≥55 years). The new findings were presented at Psych Congress, held September 15 – 19, 2026, in New Orleans, LA.
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
Amesite Announces New Sales Win Under NurseMagic® Minimum Enterprise Pricing Model
Globenewswire_fr
aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
Globenewswire_fr
Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring
Globenewswire_fr
Adventure With a Purpose: A Race Against Blindness Unveils Adventure Package Fundraiser Valued at $350,000
Globenewswire_fr
Re: Management of paracetamol (acetaminophen) toxicity
Bmj